The farnesoid X receptor (FXR) has been shown to play an important role in hepatic inflammation, fibrosis, and vasculature remodeling, and FXR agonists have recently been studied in a variety of diseases, including primary biliary cholangitis and non-alcoholic steatohepatitis (83–86). Here, NR1H4 is linked to primary biliary cholangitis.